Private Trust Company’s Royalty Pharma RPRX Stock Holding History

Private Trust Company’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$21.4K	Buy	382 +38	+11%	+$1.98K	﹤0.01%	1748
2026 Q1	$16.5K	Sell	344 -488	-59%	-$21.4K	﹤0.01%	1784
2025 Q4	$32.1K	Buy	832 +288	+53%	+$11K	﹤0.01%	1451
2025 Q3	$19.2K	Buy	544 +308	+131%	+$11.2K	﹤0.01%	1659
2025 Q2	$8.5K	Buy	236 +30	+15%	+$994	﹤0.01%	1877
2025 Q1	$6.41K	Hold	206	–	–	﹤0.01%	1950
2024 Q4	$5.25K	Sell	206 -22	-10%	-$583	﹤0.01%	1960
2024 Q3	$6.45K	Buy	228 +118	+107%	+$3.27K	﹤0.01%	1865
2024 Q2	$2.9K	Sell	110 -62	-36%	-$1.72K	﹤0.01%	2089
2024 Q1	$5.22K	Hold	172	–	–	﹤0.01%	1905
2023 Q4	$4.83K	Buy	172 +62	+56%	+$1.7K	﹤0.01%	1933
2023 Q3	$2.98K	Hold	110	–	–	﹤0.01%	2043
2023 Q2	$3.38K	Hold	110	–	–	﹤0.01%	1988
2023 Q1	$3.96K	Hold	110	–	–	﹤0.01%	1924
2022 Q4	$4K	Buy	+110	New	+$4.59K	﹤0.01%	1878

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Private Trust Company's RPRX Position: Q2 2026 in Review

Private Trust Company increased its Royalty Pharma (RPRX) stake by 11% in Q2 2026, buying an estimated $1.98K and bringing the position to 382 shares worth $21.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1748.

Private Trust Company first reported a position in RPRX in Q4 2022 and has held it in 15 quarters since. The position peaked at $32.1K in Q4 2025. 647 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Private Trust Company held 382 shares of Royalty Pharma worth $21.4K as of Q2 2026.
Private Trust Company bought 38 Royalty Pharma shares in Q2 2026, an estimated $1.98K.
Royalty Pharma made up ﹤0.01% of Private Trust Company's portfolio in Q2 2026, its #1748 holding.
Private Trust Company first reported a position in Royalty Pharma in Q4 2022 and has held it in 15 quarters since.
Private Trust Company's Royalty Pharma position peaked at $32.1K in Q4 2025.
647 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Private Trust Company's 13F filing for Q2 2026, filed 28 Jul 2026.